Who owns Iovance Biotherapeutics, Inc.?
Institutional ownership of IOVA from SEC Form 13F filings across 206 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
206
13F holders
$759.7M
value, 2026 filers
42.3%
of shares outstanding (188.9M sh)
35
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30· % of fund = share of the manager's own book · % of co. = share of IOVA's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 37.0M | $153.7M | 0.0% | 8.3% | +18.9% |
| 2 | TWO SIGMA INVESTMENTS, LP | 19.0M | $79.1M | 0.1% | 4.3% | +38.9% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 18.2M | $75.7M | 0.0% | 4.1% | -45.2% |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 14.4M | $59.9M | 0.0% | 3.2% | +23.0% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 10.3M | $43.0M | 0.0% | 2.3% | +20.4% |
| 6 | MILLENNIUM MANAGEMENT LLC | 8.5M | $35.5M | 0.0% | 1.9% | -9.4% |
| 7 | GOLDMAN SACHS GROUP INC | 5.1M | $21.2M | 0.0% | 1.1% | -41.8% |
| 8 | Nuveen, LLC | 5.0M | $20.8M | 0.0% | 1.1% | +36.4% |
| 9 | BANK OF AMERICA CORP /DE/ | 5.0M | $20.8M | 0.0% | 1.1% | -41.2% |
| 10 | MORGAN STANLEY | 5.0M | $20.7M | 0.0% | 1.1% | -19.6% |
| 11 | JANE STREET GROUP, LLC | 4.4M | $18.3M | 0.0% | 1% | +5.3% |
| 12 | NORTHERN TRUST CORP | 4.2M | $17.3M | 0.0% | 0.9% | +44.5% |
| 13 | WELLS FARGO & COMPANY/MN | 3.2M | $13.5M | 0.0% | 0.7% | +56.7% |
| 14 | Sixth Street Partners Management Company, L.P.NEW | 3.2M | $13.4M | 2.3% | 0.7% | new |
| 15 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 3.2M | $13.4M | 0.0% | 0.7% | +15.7% |
| 16 | HRT FINANCIAL LP | 3.1M | $12,886 | 0.0% | 0.7% | -11.1% |
| 17 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2.7M | $11.1M | 0.0% | 0.6% | -11.3% |
| 18 | VANGUARD FIDUCIARY TRUST CO | 2.5M | $10.6M | 0.0% | 0.6% | +16.4% |
| 19 | JPMORGAN CHASE & CO | 2.4M | $10.2M | 0.0% | 0.5% | -2.8% |
| 20 | PRICE T ROWE ASSOCIATES INC /MD/ | 2.4M | $10,050 | 0.0% | 0.5% | -23.7% |
| 21 | D. E. Shaw & Co., Inc. | 2.1M | $8.9M | 0.0% | 0.5% | -73.3% |
| 22 | CITADEL ADVISORS LLC | 2.1M | $8.8M | 0.0% | 0.5% | -19.4% |
| 23 | Woodline Partners LP | 1.4M | $5.7M | 0.0% | 0.3% | -47.2% |
| 24 | FMR LLC | 1.4M | $5.6M | 0.0% | 0.3% | +2649.2% |
| 25 | UBS Group AG | 1.3M | $5.4M | 0.0% | 0.3% | -32.6% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.